22-12-2016 дата публикации
Номер: US20160367636A1
Автор:
Ingo Flamme,
Johannes Kobberling,
Hans-Georg Lerchen,
Nils Griebenow,
Rudolf Schohe-Loop,
Sven Wittrock,
Maria Kollnberger,
Frank Wunder,
Gordon Redlich,
Andreas Knorr,
Julie Marley,
Iain Pritchard,
FLAMME INGO,
KOBBERLING JOHANNES,
LERCHEN HANS-GEORG,
GRIEBENOW NILS,
SCHOHE-LOOP RUDOLF,
WITTROCK SVEN,
KOLLNBERGER MARIA,
WUNDER FRANK,
REDLICH GORDON,
KNORR ANDREAS,
MARLEY JULIE,
PRITCHARD IAIN,
Flamme Ingo,
Kobberling Johannes,
Lerchen Hans-Georg,
Griebenow Nils,
Schohe-Loop Rudolf,
Wittrock Sven,
Kollnberger Maria,
Wunder Frank,
Redlich Gordon,
Knorr Andreas,
Marley Julie,
Pritchard Iain
Принадлежит:
The invention relates to novel polyethylene glycol (PEG) based prodrug of Adrenomedullin, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases, and to the use thereof for producing medicaments for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders. 112-. (canceled)14. The pharmaceutical composition of claim 13 , whereinn represents the number 1 or 2,{'sup': '1', 'Rrepresents hydrogen or methyl,'}{'sup': '2', 'Rrepresents linear PEG 40 kDa endcapped with a methoxy-group.'}15. The pharmaceutical composition of claim 13 , whereinn represents the number 1 or 2,{'sup': '1', 'Rrepresents hydrogen,'}{'sup': '2', 'Rrepresents linear PEG 40 kDa endcapped with a methoxy-group.'}16. The pharmaceutical composition of claim 13 , wherein the pharmaceutical form for administration by inhalation is selected from the group consisting of a powder inhaler claim 13 , a nebulizer claim 13 , a solution or a spray.17. The pharmaceutical composition of claim 13 , further comprising an active ingredient selected from the group consisting of ACE inhibitors claim 13 , angiotensin receptor antagonists claim 13 , beta-2 receptor agonists claim 13 , phosphodiesterase inhibitors claim 13 , glucocorticoid receptor agonists claim 13 , diuretics claim 13 , or recombinant angiotensin converting enzyme-2 and acetylsalicylic acid (aspirin).18. The pharmaceutical composition of claim 17 , wherein the active ingredient is selected from an ACE inhibitor selected from the group consisting of enalapril claim 17 , quinapril claim 17 , captopril claim 17 , lisinopril claim 17 , ramipril claim 17 , delapril claim 17 , fosinopril claim 17 , perindopril claim 17 , cilazapril claim 17 , imidapril claim 17 , benazepril claim 17 , moexipril claim 17 , spirapril and trandopril claim 17 , an angiotensin receptor antagonist claim 17 , selected from the group consisting of losartan claim 17 , candesartan claim 17 ...
Подробнее
